Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zap to see: electrical therapy for eye disease

NCT ID NCT02086890

Symptom relief Sponsor: Nova Southeastern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment called transcorneal electrical stimulation to see if it can improve vision in people with retinitis pigmentosa, an eye disease that causes vision loss. Twenty-one adults with the condition received the therapy, and researchers measured changes in their visual field and sharpness over about 4-6 months. The goal is to find a way to ease symptoms and slow vision decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 21 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2014

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18+ * Diagnosis of retinitis pigmentosa (RP) * Best-corrected visual acuity better than 20/400 in at least one eye * More than 20% loss of Goldmann Visual Field area (III4e test target) in at least one eye * Able and willing to participate in all study visits for a \~4-6 month period * Provide informed consent Exclusion Criteria: * Very severe vision losses in both eyes (e.g., hand motions or light perception only) with difficulty performing the proposed vision tests * Vision loss due to ocular diseases other than RP, cystoid macular edema, or cataracts * Schedules do not permit participation in all study visits * Previous acupuncture or TES treatment for RP * Inability to understand study procedures or communicate responses to visual stimuli in a consistent manner (cognitive impairment) * Dementia; Long or short-term memory loss * Unable to read or speak English * Smoking, excessive alcohol, or illegal drug use * Receiving current psychiatric care (i.e. unstable emotional and mental health status) * History of excessive bleeding * Reduced general health and/or systemic medications that may diminish the potential response to the electroacupuncture treatments * Implanted cardiac pacemaker * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retinitis pigmentosa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinitis pigmentosa

Contacts and locations

Locations

  • Nova Southeastern University; College of Optometry

    Fort Lauderdale, Florida, 33328, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.